首页> 美国卫生研究院文献>Stem Cell Research Therapy >Mesenchymal stem cells improve mouse non-heart-beating liver graft survival by inhibiting Kupffer cell apoptosis via TLR4-ERK1/2-Fas/FasL-caspase3 pathway regulation
【2h】

Mesenchymal stem cells improve mouse non-heart-beating liver graft survival by inhibiting Kupffer cell apoptosis via TLR4-ERK1/2-Fas/FasL-caspase3 pathway regulation

机译:间充质干细胞通过TLR4-ERK1 / 2-Fas / FasL-caspase3途径抑制Kupffer细胞凋亡从而改善小鼠非心脏跳动的肝移植存活率

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundLiver transplantation is the optimal treatment option for end-stage liver disease, but organ shortages dramatically restrict its application. Donation after cardiac death (DCD) is an alternative approach that may expand the donor pool, but it faces challenges such as graft dysfunction, early graft loss, and cholangiopathy. Moreover, DCD liver grafts are no longer eligible for transplantation after their warm ischaemic time exceeds 30 min. Mesenchymal stem cells (MSCs) have been proposed as a promising therapy for treatment of certain liver diseases, but the role of MSCs in DCD liver graft function remains elusive.
机译:背景肝移植是终末期肝病的最佳治疗选择,但器官短缺严重限制了其应用。心脏死亡后的捐赠(DCD)是一种替代方法,可以扩大供体库,但面临诸如移植物功能障碍,早期移植物丢失和胆管病的挑战。此外,DCD肝移植物的温暖缺血时间超过30分钟后不再适合移植。间充质干细胞(MSCs)已被提出作为治疗某些肝脏疾病的一种有前途的疗法,但是MSCs在DCD肝移植功能中的作用仍然难以捉摸。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号